Volume 51, No. 1/2013(January)
The online-version will be updated before the print-version of this Journal is published. Upon request we will send the password and user name by e-mail. The online-service is only available for subscribers of the print-version, if proof of purchase is submitted.
The use of the online-version will be charged with an extra fee (additional to the subscription of the print-version). The service can be used until December 31st of the year of subscription.
|
| Price of the complete print-issue: 30.00$ |
Add to Cart
|
Original Research
Use of contraindicated drugs in patients with chronic liver disease: a therapeutic dilemma
Mohammad Sistanizad and Gregory M. Peterson
Price
42.00 $
Page No. 1
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (1-4)
Use of contraindicated drugs in patients with chronic liver disease: a therapeutic dilemma
Mohammad Sistanizad1 and Gregory M. Peterson2
1Department of Pharmacotherapy, School of Pharmacy, Shahid Beheshti Medical University, Iran, and 2Unit for Medication Outcomes Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia
Objective: To investigate the prevalence of prescribing of contraindicated drugs or those requiring caution, in hospital inpatients with chronic liver disease. Methods: The medical records and drug charts of adult hospitalized patients, consecutively admitted with clinical documentation and biochemical evidence of chronic liver disease, were studied retrospectively. Comparison was made between the prescription details for each drug and the recommendations for use in patients with liver disease under the approved product information, which indicates drugs that could be hepatotoxic and those that could have markedly altered pharmacokinetics or pharmacodynamics in chronic liver disease. Results: 49 eligible patients with both clinical documentation and confirmatory biochemical evidence of chronic liver disease were identified. Of these, 15 had received at least 1 contraindicated medication during hospitalization, with diazepam being the most common. 31 patients had received at least 1 drug which requires precaution in liver disease, with propranolol being the most common. Conclusion: The use of contraindicated drugs or those requiring caution, occurred frequently in hospital patients with chronic liver disease. This could reflect the somewhat limited evidence base and the perhaps overly cautious nature of the official product information.Correspondence to:
Gregory M. Peterson, PhD, MBA, FSHP, FACP
Unit for Medication Outcomes Research and Education (UMORE)
School of Pharmacy, University of Tasmania
Private Bag 26, Hobart Tasmania 7001, Australia
Email: [email protected]
Original Research
The effect of naltrexone on the perception and distress in tinnitus: an open-label pilot study
Sven Vanneste, Andréia Azevedo and Dirk De Ridder
Price
42.00 $
Page No. 5
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (5-11)
The effect of naltrexone on the perception and distress in tinnitus: an open-label pilot study
Sven Vanneste1,2, Andréia Azevedo3 and Dirk De Ridder1
1Brai2n, Tinnitus Research Initiative Clinic Antwerp and Department of Neurosurgery, 2Department of Translational Neuroscience, Faculty of Medicine, University of Antwerp, Belgium, and 3OTOSUL, Clinical and Research Tinnitus Center, Volta Redonda, Brazil
Objective: Tinnitus is a perceived sensation of sound without actual acoustic stimulation. Currently there are no standardized drug therapies for the treatment of tinnitus patients. A potential novel treatment for chronic tinnitus is naltrexone. Tinnitus can be considered an auditory phantom phenomenon similar to phantom pain. Naltrexone acts predominantly on μ-opioid receptors which are present in multiple areas of the brain, including the thalamus, dorsal part of the anterior cingulate, insula, amygdala, nucleus accumbens, and ventromedial to orbitofrontal cortex. These areas overlap with the areas involved in tinnitus-related distress. The aim of the present study is to investigate three doses of naltrexone, namely 5, 12.5, and 50 mg and determine their influence on tinnitus complaints. We conducted a 4-week single-center, open-label treatment study. Subjects and methods: 86 patients received the drug treatment, while 30 patients received no treatment. Results: Overall tinnitus distress was significantly reduced for the drug treatment group, while for the waiting control group this was not the case. No significant effect could be obtained for tinnitus intensity. A closer look at the data indicates that this effect is mainly generated due to a significant difference in the 50 mg drug treatment group for tinnitus distress. Conclusion: our results indicate that naltrexone might have an effect on tinnitus distress and more particularly higher doses of naltrexone.Correspondence to:
Sven Vanneste, PhD
TRI Tinnitus Clinic, BRAI2N, University, Hospital Antwerp
Wilrijkstraat 10, 2650 Edegem, Belgium
Email: [email protected] http://www.brai2n.com
Original Research
Economic prescribing of corticosteroid nasal sprays in Germany. Comparison of mometasone and budesonide nasal sprays on the basis of the DDD, the PDD and reference prices
Beril Becker, Silvia Kruppert and Karel Kostev
Price
42.00 $
Page No. 12
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (12-18)
Economic prescribing of corticosteroid nasal sprays in Germany. Comparison of mometasone and budesonide nasal sprays on the basis of the DDD, the PDD and reference prices
Beril Becker1, Silvia Kruppert2 and Karel Kostev2
1MSD Sharp & Dohme GmbH, Haar, and 2IMS Health GmbH & Co. OHG, Frankfurt,
Germany
Aim: According to the German Social Security Code (SGB V), drugs should be prescribed on a cost-effective basis. An attempt is made to achieve this in Germany with the help of the DDD system and reference prices. Taking the example of the most frequently prescribed corticosteroid nasal sprays containing the active substances budesonide (BNS) or mometasone (MNS), we will show here that the DDD system is not necessarily suitable for tapping economic reserves. Despite the pharmacologic differences between the two substances, a uniformly defined daily dose (DDD) is assumed for both. Moreover, since 2006 they have formed a reference-price group of nasally administered medication with other active substances. Products were compared with regard to potential differences in patient populations and resulting treatment costs. The extent to which the two instruments are suitable for tapping economic reserves were estimated. Methods: We analyzed longitudinal diagnostic and prescription data in the IMS® Disease Analyzer Database from the period 2006 to July 2010. Results: In total we analyzed data from 16,163 MNS and 4,218 BNS patients from GP practices plus 11,103 MNS and 2,521 BNS patients from ENT practices. The average quantity prescribed per patient differed in favor of MNS by –111.5 (for first prescriptions) to –260.1 puffs (after 730 days) in GP practices and by –137.3 to –488.3 puffs in ENT practices (p < 0.001). The mean calculated treatment cost per year from the point of view of the statutory health insurer was 20.40 € (GP practices) and 30.50 € (ENT practices) for MNS compared to 22.40 € (GP practices) and 32.10 € (ENT practices) for BNS. Based on the price level after the 2011 referenceprice adjustment, the treatment costs are 16.40 € (GP practices) and 24.20 € (ENT practices) for MNS versus 21.20 € (GP practices) and 32.30 € (ENT practices) for BNS. Conclusion: The volumes of MNS actually prescribed are significantly lower than those of BNS in the compared patient populations. Based on the actual consumption of the substances, there is no treatment-cost advantage for BNS in comparison to MNS from the statutory health insurer’s point of view. By contrast, the reference-price adjustment results in a greater reduction of treatment costs for mometasone, so that in this case the statutory health insurer is able to tap economic reserves. Both the comparative parameters used for calculating the reference price and the DDD system are only conditionally suitable for tapping economic reserves for drugs.Correspondence to:
Dr. Beril Becker
MSD Sharp & Dohme GmbH
Lindenplatz 1, 85540 Haar, Germany
Email: [email protected]
Original Research
Clinical usefulness of doripenem (DRPM), a carbapenem antimicrobial drug, for the treatment of patients with acute cholangitis. Retrospective study
Yuji Sakai, Toshio Tsuyuguchi, Kazuki Kato, Harutoshi Sugiyama, Takao Nishikawa, Makoto Takahashi and Osamu Yokosuka
Price
42.00 $
Page No. 19
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (19-25)
Clinical usefulness of doripenem (DRPM), a carbapenem antimicrobial drug, for the treatment of patients with acute cholangitis. Retrospective study
Yuji Sakai1,2, Toshio Tsuyuguchi1, Kazuki Kato2, Harutoshi Sugiyama1, Takao Nishikawa1, Makoto Takahashi3 and Osamu Yokosuka1
1Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Japan, 2Department of Internal Medicine, Funabashi Central Hospital, Funabashi City, Chiba, Japan, and 3Department of Surgery, Funabashi Central Hospital, Funabashi City, Chiba, Japan
Aim: We investigated the usefulness of doripenem (DRPM), a carbapenem antimicrobial drug, for the treatment of acute cholangitis. Methods: 28 patients who received a diagnosis of moderate or severe cholangitis were included in this investigation. 23 patients had moderate cholangitis; 5 patients had severe cholangitis. When moderate or severe cholangitis was diagnosed, administration of DRPM and endoscopic drainage were performed. The dose of DRPM was fixed at 0.5 g, 3 times daily. Evaluation of clinical findings (abdominal pain and body temperature) and blood test findings (WBC, CRP, ALT, ALP, and T-Bil) was performed before and on Day 5 after administration. Results: Endoscopic drainage was successful in all patients. After administration of DRPM, a significant improvement was observed in all endpoints of both clinical findings and blood test findings (p < 0.05). No adverse events due to administration of DRPM were observed. Conclusion: It was suggested that administration of DRPM may be clinically useful for the treatment of moderate and severe cholangitis.Correspondence to:
Yuji Sakai, MD
Department of Medicine and Clinical Oncology
Graduate School of Medicine, Chiba University
Inohana 1-8-1, Chuou-ku, Chiba City, 260-8670, Japan
Email: [email protected]
Original Research
Changes in gastric pH and in pharmacokinetics of ulipristal acetate – a drug-drug interaction study using the proton pump inhibitor esomeprazole
Oliver Pohl, Ian Osterloh, Véronique Lecomte and Jean-Pierre Gotteland
Price
42.00 $
Page No. 26
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (26-33)
Changes in gastric pH and in pharmacokinetics of ulipristal acetate – a drug-drug interaction study using the proton pump inhibitor esomeprazole
Oliver Pohl1, Ian Osterloh1,2, Véronique Lecomte1 and Jean-Pierre Gotteland1
1PregLem SA, Geneva, Switzerland and 2OsterMed Ltd., Birmingham, UK
Objective: Ulipristal acetate is a novel selective progesterone receptor modulator for the treatment of benign gynecological conditions such as uterine myoma. As a Biopharmaceutical Classification System (BCS) II compound, it is highly soluble at low pH but has low solubility at neutral conditions. Esomeprazole, a proton pump inhibitor used widely for treatment of gastric and duodenal ulcers, efficiently increases gastric pH. Thus, the aim of this study was to determine the effects of esomeprazole on the pharmacokinetics of ulipristal acetate. Materials and methods: This was a nonrandomized, single sequence, 2 period, open, study in 18 healthy female subjects. Subjects received oral ulipristal acetate tablets (10 mg) once on Days 1 and 13 and daily esomeprazole administrations (20 mg) from Days 9 through 14. Results: Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 – 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 – 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0–t 1.15 (1.02 – 1.31) and AUC0–∞ (1.11 (0.98 – 1.27)), respectively. A total of 6 adverse events were reported by 4 subjects, none of them being serious. Conclusions: Concomitant use of ulipristal acetate with esomeprazole at therapeutic concentrations led to a modified absorption rate while exposure in terms of AUC remained close to bioequivalence limits. In the context of chronic administration of ulipristal acetate, no clinically significant effects are expected from co-administration with drugs increasing gastric pH.Correspondence to:
Dr. Oliver Pohl
NCD & Phase I Project Director/Product
Development and Manufacturing
PregLem SA
Chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates Geneva, Switzerland
Email: [email protected]
Extended Abstracts
The 10th Annual Meeting of CESAR in Essen June 28 – 30, 2012, Germany – Editorial
Ulrich Jaehde, Ralf Hilger, Thomas Gauler, Daniel Sehrt
Page No. 34
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (34)
The 10th Annual Meeting of CESAR in Essen June 28 – 30, 2012, Germany – Editorial
Ulrich Jaehde, Ralf Hilger, Thomas Gauler, Daniel Sehrt
Extended Abstracts
NF-κB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model
Maria I. Körber, Simone Klingenbrunner, Rupert Bartsch, Günther G. Steger and Robert M. Mader
Page No. 35
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (35-37)
NF-κB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model
Maria I. Körber, Simone Klingenbrunner, Rupert Bartsch, Günther G. Steger and Robert M. Mader
Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria
Correspondence to:
Univ.-Prof Dipl.-Ing Dr. Robert Mader
Universitätsklinik für Innere Medizin
Währinger Gürtel 18-20
1090 Vienna, Austria
Email: [email protected]
Extended Abstracts
Prediction of cytotoxic drug concentrations occurring on the day of autologous stem cell rescue during a high-dose chemotherapy regimen
Valerie Nock, Andreas Lindauer, Ulrich Jaehde and Charlotte Kloft
Page No. 38
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (38-40)
Prediction of cytotoxic drug concentrations occurring on the day of autologous stem cell rescue during a high-dose chemotherapy regimen
Valerie Nock1,2, Andreas Lindauer3, Ulrich Jaehde3 and Charlotte Kloft1
1Institute of Pharmacy, Clinical Pharmacy and Biochemistry, Freie Universität Berlin, 2Graduate Research Training Program PharMetrX, and 3Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany
Correspondence to:
Prof. Dr. C. Kloft
Institute of Pharmacy, Clinical Pharmacy and
Biochemistry
Freie Universitaet Berlin
Kelchstr. 31, 12169 Berlin, Germany
Email: [email protected]
Extended Abstracts
New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents
Katharina Mahal, Bernhard Biersack and Rainer Schobert
Page No. 41
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (41-43)
New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents
Katharina Mahal, Bernhard Biersack and Rainer Schobert
Chair of Organic Chemistry, University Bayreuth, Bayreuth, Germany
Correspondence to:
Katharina Mahal
University Bayreuth
Universitaetsstr. 30, NW I
95440 Bayreuth, Germany
Email: [email protected]
Extended Abstracts
Synergistic “gold effects” of anti-vascular 4,5-diarylimidazol-2-ylidene gold(I) carbene complexes
Julienne Münzner, Bernhard Biersack, Leonard Kaps, Rainer Schobert and Florenz Sasse
Page No. 44
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (44-46)
Synergistic “gold effects” of anti-vascular 4,5-diarylimidazol-2-ylidene gold(I) carbene complexes
Julienne Münzner1, Bernhard Biersack1, Leonard Kaps1, Katharina Mahal1, Rainer Schobert1 and Florenz Sasse2
1Chair of Organic Chemistry, University Bayreuth, Bayreuth and 2Department of Chemical Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany
Correspondence to:
Julienne Münzner
Chair of Organic Chemistry, NWI
University Bayreuth
Universitätsstr. 30
95440 Bayreuth, Germany
Email: [email protected]
Short Report
Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro
Patrick Schmitz, Ursula Gerber, Eva Jüngel, Norbert Schütze, Roman Blaheta and Gerd Bendas
Page No. 47
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (47-50)
Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro
Patrick Schmitz1*, Ursula Gerber1*, Eva Jüngel2, Norbert Schütze3, Roman Blaheta2 and Gerd Bendas1
1Department of Pharmacy, University Bonn, Bonn, 2Frankfurt University Hospital, Center of Surgery, Research Laboratory, Frankfurt am Main, and 3Orthopedic Center for Musculoskeletal Research, University Würzburg, Würzburg, Germany
*These authors contribute equally to this work.
Correspondence to:
Patrick Schmitz, M.Sc.
Department of Pharmacy
University Bonn
53121 Bonn, Germany
Email: [email protected]
Extended Abstracts
Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines
Ali Haydar Acikelli, Sebastian Gustmann, Walter Bardenheuer, Jacqueline Klein, Ulrike Dembinski, Bastian Kohl, King Tou Yip, Ali Nazif, Raphael Stoll, Dirk Strumberg and David Díaz-Carballo
Page No. 51
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (51-53)
Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines
Ali Haydar Acikelli1, Sebastian Gustmann1, Walter Bardenheuer1, Jacqueline Klein1, Ulrike Dembinski1, Bastian Kohl2, King Tou Yip2, Ali Nazif2, Raphael Stoll2, Dirk Strumberg1 and David Díaz-Carballo1
1Department of Molecular Oncology, Marienhospital Herne, Herne, and 2Faculty of Chemistry and Biochemistry, Biomolecular NMR Spectroscopy, Ruhr-University Bochum, Bochum, Germany
Correspondence to:
Dr. David Díaz-Carballo
Marienhospital Herne, Katholische Stiftung
Institut für Molekulare Onkologie und Substanzentwicklung
Düngelstr. 33, 44625 Herne, Germany
Email: [email protected]
Extended Abstracts
Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity
David Díaz-Carballo, Sebastian Gustmann, Ali Haydar Acikelli, Walter Bardenheuer, Jacqueline Klein, Ulrike Dembinski, Bastian Kohl, King Tou Yip, Ali Nazif, Raphael Stoll and Dirk Strumberg
Price
42.00 $
Page No. 54
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (54-55)
Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity
David Díaz-Carballo1, Sebastian Gustmann1, Ali Haydar Acikelli1, Walter Bardenheuer1, Jacqueline Klein1, Ulrike Dembinski1, Bastian Kohl2, King Tou Yip2, Ali Nazif2, Raphael Stoll2 and Dirk Strumberg1
1Department of Molecular Oncology, Marienhospital Herne, Herne, and 2Faculty of Chemistry and Biochemistry, Biomolecular NMR Spectroscopy, Ruhr-University Bochum, Bochum, Germany
Correspondence to:
Dr. David Díaz-Carballo
Marienhospital Herne, Katholische Stiftung
Institut für Molekulare Onkologie und Substanzentwicklung
Düngelstr. 33, 44625 Herne, Germany
Email: [email protected]
Extended Abstracts
5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer
Martina Blaschke, Silke Cameron, Colin Goeschen and Giuliano Ramadori
Page No. 56
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (56-58)
5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer
Martina Blaschke, Silke Cameron, Colin Goeschen and Giuliano Ramadori
Department of Gastroenterology and Endocrinology, University Medicine Göttingen, Göttingen, Germany
Correspondence to:
Dr. Silke Cameron, MD
Department of Gastroenterology and Endocrinology
University Medical Center Göttingen
Robert-Koch-Straße 40
37075 Göttingen, Germany
Email: [email protected]
Short Report
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer
Julia Lehner, Oliver J. Stötzer, Debora M.I. Fersching, Dorothea Nagel and Stefan Holdenrieder
Page No. 59
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (59-62)
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer
Julia Lehner1, Oliver J. Stötzer2, Debora M.I. Fersching1, Dorothea Nagel1 and Stefan Holdenrieder1,3
1Institute of Clinical Chemistry, University Hospital Munich-Grosshadern, 2Hematology/Oncology Outpatient Center Munich, Munich and 3Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany
Correspondence to:
Stefan Holdenrieder, MD
Institute of Clinical Chemistry and Clinical
Pharmacology
University Hospital Bonn
Sigmund-Freud-Strasse 25
53127 Bonn, Germany
Email: [email protected]
Short Report
CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy
Yvonne Nadine Fahmueller, Dorothea Nagel, Ralf-Thorsten Hoffmann, Klaus Tatsch, Tobias Jakobs, Petra Stieber and Stefan Holdenrieder
Page No. 63
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (63-66)
CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy
Yvonne Nadine Fahmueller1, Dorothea Nagel1, Ralf-Thorsten Hoffmann2,4, Klaus Tatsch3,5, Tobias Jakobs2,6, Petra Stieber1 and Stefan Holdenrieder1,7
1Institute of Clinical Chemistry, 2Institute of Clinical Radiology, 3Clinics of Nuclear Medicine, University-Hospital Munich-Grosshadern, Munich, 4Institute of Radiological Diagnostics, Hospital of the Technical University Dresden, Dresden, 5Department of Nuclear Medicine, Municipal Hospital Karlsruhe Inc. Karlsruhe, 6Department of Diagnostics and Interventional Radiology, Hospital Barmherzige Brüder Munich, Munich, and 7Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany
Correspondence to:
Stefan Holdenrieder, MD
Institute of Clinical Chemistry and Clinical
Pharmacology
University Hospital Bonn
Sigmund-Freud Straße 15
53127 Bonn, Germany
Email: [email protected]
Extended Abstracts
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients
Christin Wittwer, Stefan Boeck, Volker Heinemann, Michael Haas, Petra Stieber, Dorothea Nagel and Stefan Holdenrieder
Page No. 67
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (67-69)
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients
Christin Wittwer1, Stefan Boeck2, Volker Heinemann2, Michael Haas2, Petra Stieber1, Dorothea Nagel1 and Stefan Holdenrieder1,3
1University Hospital Munich, Institute of Clinical Chemistry, 2University Hospital Munich, Department of Internal Medicine III and Comprehensive Cancer Center, Munich, and 3University Hospital Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, Bonn, Germany
Correspondence to:
Stefan Holdenrieder, MD
Institute of Clinical Chemistry and Clinical
Pharmacology
University Hospital Bonn
Sigmund-Freud Str. 15, 53127 Bonn, Germany
Email: [email protected]
Short Report
Are low molecular weight heparins able to sensitize chemoresistant tumor cells?
Daniel P. Stölting, Ulrich Jaehde, Michael Wiese and Gerd Bendas
Page No. 70
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (70-73)
Are low molecular weight heparins able to sensitize chemoresistant tumor cells?
Daniel P. Stölting, Ulrich Jaehde, Michael Wiese and Gerd Bendas
Pharmaceutical Department, University of Bonn, Bonn, Germany
Correspondence to:
Daniel P. Stölting, M.Sc.
WG Prof. Gerd Bendas
Pharmaceutical Department
University of Bonn
An der Immenburg 4, 53121 Bonn
Email: [email protected]
Extended Abstracts
Thrombocytopenia following high-dose chemotherapy with carboplatin, etoposide and thiotepa in patients with testicular germ cell cancer
Iris Minichmayr, Valerie Nock, Ulrich Jaehde and Charlotte Kloft
Page No. 74
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (74-76)
Thrombocytopenia following high-dose chemotherapy with carboplatin, etoposide and thiotepa in patients with testicular germ cell cancer
Iris Minichmayr1,2, Valerie Nock1,2, Ulrich Jaehde3 and Charlotte Kloft1
1Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, 2Graduate Research Training Program PharMetrX, and 3Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Bonn, Germany
Correspondence to:
Prof. Dr. Charlotte Kloft
Department of Clinical Pharmacy and Biochemistry
Institute of Pharmacy
Freie Universitaet Berlin
Kelchstraße 31, 12169 Berlin, Germany
Email: [email protected]
Extended Abstracts
Validation of markers for the screening and identification of disseminating tumor cells in lymph nodes and bone marrow
Michael Alexander, Benedikt Reising, Sarah Schumacher, Christoph Sproll and Nikolas H. Stoecklein
Page No. 77
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (77-79)
Validation of markers for the screening and identification of disseminating tumor cells in lymph nodes and bone marrow
Michael Alexander1, Benedikt Reising1, Sarah Schumacher1, Christoph Sproll2 and Nikolas H. Stoecklein1
1Experimental Surgical Oncology, Department of General, Visceral and Pediatric Surgery, and 2Department for Cranio- and Maxillofacial Surgery, Heinrich-Heine University of Düsseldorf, Düsseldorf, Germany
Correspondence to:
Dr. Michael Alexander
AG Experimental
Chirurgical Oncology
Department of General, Visceral and Pediatric
Surgery
Heinrich-Heine University of Düsseldorf
Moorenstraße 5, 40225 Düsseldorf, Germany
Email: [email protected]
Short Report
DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy
Nikolaus Kohles, Dorothea Nagel, Dietrich Jüngst, Petra Stieber and Stefan Holdenrieder
Page No. 80
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (80-83)
DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy
Nikolaus Kohles1,2, Dorothea Nagel1, Dietrich Jüngst3, Petra Stieber1, Stefan Holdenrieder1,4
1Institute of Clinical Chemistry, University-Hospital Munich-Grosshadern, Munich, 2Department of Otorhinolaryngology, Helios-Klinikum Erfurt, Erfurt, 3Medical Clinic II, University-Hospital Munich-Grosshadern, Munich, and 4Institute of Clinical Chemistry and Clinical Pharmacology, University-Hospital Bonn, Bonn, Germany
Correspondence to:
Stefan Holdenrieder, MD
Institut für Klinische Chemie und Klinische
Pharmakologie
Universitätsklinikum Bonn
Sigmund-Freud-Straße 25
53127 Bonn, Germany
Email: [email protected]
Extended Abstracts
Design of clinical studies: Adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)
Daniel Schrimpf, Christian Manegold and Lothar R. Pilz
Page No. 84
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (84-86)
Design of clinical studies: Adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)
Daniel Schrimpf1, Christian Manegold2 and Lothar R. Pilz2
1Deutsches Krebsforschungszentrum (DKFZ), Department of Biostatistics, and 2University of Heidelberg, Medical Faculty Mannheim, Heidelberg, Germany
Correspondence to:
Daniel Schrimpf, Dipl.-Inform. Med
Deutsches Krebsforschungszentrum (DKFZ)
Department of Biostatistics
Im Neuenheimer Feld 280
69120 Heidelberg, Germany
Email: [email protected]
Extended Abstracts
Sarcomatoid non-small cell lung cancer responding to sunitinib
Beate Schultheis, Gerhard Kummer and Dirk Strumberg
Page No. 87
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (87-88)
Sarcomatoid non-small cell lung cancer responding to sunitinib
Beate Schultheis, Gerhard Kummer and Dirk Strumberg
Department of Hematology and Oncology, Marienhospital Herne, Ruhr University Bochum, Germany
Correspondence to:
Dr. Beate Schultheis
Department of Hematology and Oncology
Ruhr University Bochum
Marienhospital Herne
Hölkeskampring 40
44625 Herne, Germany
Email: [email protected]
Extended Abstracts
Pharmacometrics and systems biology in oncology: Is there an intersection?
Charlotte Kloft
Page No. 89
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (89-90)
Pharmacometrics and systems biology in oncology: Is there an intersection?
Charlotte Kloft
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany
Correspondence to:
Prof. Dr. Charlotte Kloft
Department of Clinical Pharmacy and Biochemistry
Freie Universitaet Berlin
Kelchstraße 31, 12169 Berlin, Germany
Email: [email protected]
